Cardiac Dimensions, the leader in minimally invasive repair therapies for functional mitral regurgitation (FMR), today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the pivotal CARILLON trial.
A single-center study recently published in the Journal of Invasive Cardiology noted that treatment with Cardiac Dimensions’ Carillon® Mitral Contour System® resulted in significant improvement of functional (secondary) mitral regurgitation (FMR), a condition that can increase the symptoms of heart failure.
Cardiac Dimensions®, a medical device company dedicated to addressing functional mitral regurgitation using an innovative, minimally invasive approach, today announced the appointment of Gregory D. Casciaro as President and Chief Executive Officer (CEO), effective immediately.
The CARILLON® Mitral Contour System® is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR).
Cardiac Dimensions® just announced that the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a prospective, double-blind, randomized multi-center trial, evaluating the company’s minimally-invasive CARILLON® Mitral Contour System®.
Cardiac Dimensions® today announced the addition of $15.2 million to its previously announced financing.
Cardiac Dimensions® announced the addition of $8.5 million to its previously announced financing. Arboretum Ventures, a Michigan-based venture capital firm specializing in the healthcare sector, joined an international syndicate of institutional investors from Australia, the U.S. and Canada that includes M.H. Carnegie & Co. and Lumira Capital. Together with the financing announced in April, the aggregate amount raised in this round is $28.5 million.